A multicenter, randomized phase III study of bortezomib and dexamethasone compared with dexamethasone alone as induction treatment followed by high dose melphalan (HDM) and autologous stem cell transplantation (SCT) in patients with de novo amyloid light chain (AL) amyloidosis.

Trial Profile

A multicenter, randomized phase III study of bortezomib and dexamethasone compared with dexamethasone alone as induction treatment followed by high dose melphalan (HDM) and autologous stem cell transplantation (SCT) in patients with de novo amyloid light chain (AL) amyloidosis.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Bortezomib (Primary) ; Autologous stem cell therapy; Dexamethasone
  • Indications Amyloidosis
  • Focus Therapeutic Use
  • Acronyms HOVON 104; HOVON104AL-Amyloidosis
  • Sponsors Janssen
  • Most Recent Events

    • 25 Jun 2017 Status changed to active, no longer recruiting as per results presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 Primary endpoint has not been met. (Hematological CR rate 6 months after auto-SCT.) as per results presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top